Table 1.
Patients’ demographic and clinical characteristics
| Patients (n) | 789 |
| Age at diabetes diagnosis (years) | 53.3 ± 10.5 |
| Sex (male/female) | 373/416 |
| Smoking (none/former/current) | 598/45/146 |
| Hypertension (%) | 597 (75.7) |
| Hyperlipidemia (%) | 758 (96.1) |
| Body mass index (kg/m2) | 26.8 ± 3.9 |
| Mean number of measurements | 45.0 ± 24.5 |
| Mean SBP (mmHg) | 137 ± 10 |
| Mean number of measurement | 63.0 ± 28.9 |
| SD of SBP (mmHg) | 14.7 ± 3.6 |
| Delta SBP (mmHg) | 71.7 ± 25.0 |
| Mean DBP (mmHg) | 73.5 ± 6.3 |
| SD of DBP (mmHg) | 7.4 ± 2.0 |
| Delta DBP (mmHg) | 37.7 ± 14.3 |
| Hemoglobin A1c (%) (mmol/mol) |
7.6 ± 1.0 (60.0 ± 10.9) |
| Mean number of measurements | 34.8 ± 10.9 |
| Total cholesterol (mg/dL) | 193.4 ± 28.6 |
| Mean number of measurements | 11.9 ± 5.8 |
| High-density lipoprotein (mg/dL) | 38.5 ± 10.7 |
| Low-density lipoprotein (mg/dL) | 118.7 ± 20.3 |
| Triglyceride (mg/dL) | 149.8 ± 113.8 |
| Initial eGFR (mL/min/1.73 m2) | 88.6 ± 22.7 |
| Mean number of measurements | 17.9 ± 6.7 |
| Final eGFR (mL/min/1.73 m2) | 75.1 ± 27.6 |
| Clinical Events during10-year follow-up | |
| CVD a (%) | 115 (14.6) |
| Interval from diabetes diagnosis (years) | 5.2 ± 3.1 |
| Change in CKD stage | 1.2 ± 0.7 |
| Renal function impairment (%) | 309 (39.2) |
| CKD stage 4 or 5 (%) | 83 (10.5) |
| Total follow-up period (days) | 4451 ± 453 |
Abbreviations: SBP systolic blood pressure, DBP diastolic blood pressure, SD standard deviation, eGFR estimated glomerular filtration rate, CVD cardiovascular disease, CKD chronic kidney disease
aDefined as coronary artery disease or myocardial infarction, and ischemic stroke or transient ischemic attack